Skip to main content

Remote Job Finders (RJF)

J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer

Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma therapy, as analysts tout increased accountability brought by the FDA’s new policy of publicizing complete response letters; and Revolution Medicines’ pancreatic cancer candidate doubled survival in one of cancer’s most intractable foes.

50 employees impacted as Astellas closes Universal Cells’ Seattle office

By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.
Scroll to top